Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false statements and failing to disclose material design changes to its G6 and G7 devices, which may have compromised their reliability and safety [1][2]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized material design changes to the G6 and G7 devices, which were not approved by the U.S. Food and Drug Administration (FDA) [2]. - These design changes reportedly rendered the G6 and G7 devices less reliable than previous versions, posing a significant health risk to users who depend on accurate glucose readings [2]. - The enhancements claimed by DexCom for the G7 device, including its reliability, accuracy, and functionality, were allegedly overstated [2]. - The company is accused of downplaying the severity of issues and health risks associated with the altered G7 devices [2]. - As a result of these actions, DexCom faces increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by DexCom were claimed to be materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who acquired DexCom shares during the class period (July 26, 2024, to September 17, 2025) are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 26, 2025 [3].

Core Viewpoint - DexCom, Inc. is expected to report strong third-quarter results, driven by operational momentum, patient growth, and improved access, with a raised full-year revenue outlook reflecting confidence in demand and reimbursement expansion [1][2][8] Operational Performance - The company enters Q3 with solid operational momentum, supported by continued patient growth and a strengthening global footprint [2][8] - Commercial execution is a focal point, with healthy uptake of the product portfolio, particularly G7 and Stelo, despite competitive pressures [3][8] - Improved channel operations and access expansion are likely to have contributed to stronger prescription trends and pharmacy channel throughput [4][6] U.S. Market Dynamics - Strong new patient additions and integration with over 100 health systems have supported smoother prescription workflows [4][5] - Coverage for Type 2 diabetes patients not on insulin has broadened, with access secured through a major PBM, potentially covering around six million lives [4][5] International Trends - The international business has maintained healthy growth, driven by expanding Type 2 access and market penetration in regions like Ontario, France, and Japan [7][10] - Management expects continued international contribution, supported by growing awareness among primary care providers and improving prescription visibility [9][10] Stelo and New Market Initiatives - Stelo is an emerging growth vector, with over 400,000 app downloads and partnerships enhancing user engagement [11][12] - While currently a small financial contributor, Stelo is expected to represent 2% to 3% of 2025 sales, with ongoing feature expansion likely to accelerate adoption [12] Financial Outlook and Margin Progress - The company raised its full-year 2025 revenue outlook to $4.60 to $4.625 billion, reflecting 14% to 15% growth [13] - Gross margin is projected at approximately 62%, with expectations for sequential improvement as freight costs ease and inventory levels normalize [13][14] Estimate Picture - The Zacks Consensus Estimate for Q3 revenues is $1.18 billion, indicating an 18.4% improvement year-over-year, with EPS expected to increase by 26.7% to 57 cents [15] Long-Term Investment Visibility - Dexcom's long-term growth is supported by the expansion of the CGM category into Type 2 and pre-diabetes markets, with improving coverage and digital workflow integration [24][25] - Innovation remains central to the strategy, with advancements in product offerings and software enhancing usability and user engagement [25][26]

Core Points - A shareholder class action lawsuit has been filed against DexCom, alleging that the company made materially false and misleading statements regarding the G6 and G7 devices [1] - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7, which compromised their reliability and presented health risks to users [1] - The allegations include overstated claims about the enhancements and functionality of the G7, as well as downplaying the severity of issues related to the devices [1] - The lawsuit suggests that these actions have exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [1] Legal Context - Shareholders who purchased DexCom shares between July 26, 2024, and September 17, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is December 26, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of DexCom, Inc. [1] Company Investigation - The investigation focuses on whether DexCom's leadership has acted in the best interests of shareholders [1] - Long-term shareholders of DexCom may have the opportunity to pursue corporate governance reforms and seek financial remedies [1] Potential Outcomes - Shareholders could potentially receive a court-approved financial incentive award or other forms of relief and benefits [1]

Core Viewpoint - The investigation by Hunterbrook Media highlights significant safety, operational, and financial concerns regarding DexCom, Inc.'s G7 continuous glucose monitor, indicating a decline in the company's reputation and potential risks to patient health [2][5]. Financial Performance - DexCom's share price was $65.41 as of October 15th, with trailing and forward P/E ratios of 46.79 and 25.64 respectively [1]. - Financial indicators suggest deteriorating fundamentals, including a surge in days sales outstanding and a doubling of work-in-process inventory, raising concerns about revenue recognition practices [4]. Product Issues - The G7 sensor's performance has been compromised due to a secret alteration of a key component, leading to underperformance in accuracy metrics and resulting in the FDA classifying the device as "adulterated" [2][3]. - Users have reported serious inaccuracies, leading to hospitalizations and fatalities, including a case linked to a device failure [2][3]. Corporate Culture and Management - Former employees have criticized the corporate culture for prioritizing profit margins over safety, with inadequate technical oversight and rushed design decisions to compete with Abbott's Freestyle Libre 3 [3]. - There are indications of systemic issues within the company, evidenced by executive departures, insider sales, and repeated product recalls [4]. Competitive Landscape - DexCom faces increasing competition from Abbott's superior devices and potential changes in Medicare policies, which could threaten its market share [4]. - The company's own initiatives, such as the Stelo device, are also experiencing accuracy problems and legal challenges [4].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is presented as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI [3][7] - This company is characterized as a "toll booth" operator in the AI energy boom, benefiting from the surge in demand for electricity driven by AI advancements [4][5] Market Position - The company is noted for its unique position in the market, being debt-free and holding a significant cash reserve, which is nearly one-third of its market capitalization [8] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth engines in the AI sector [9][10] Future Trends - The article discusses the broader trends of onshoring and U.S. LNG exports, positioning the company as a beneficiary of these developments under the current political climate [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the importance of investing in AI-related companies [12] Conclusion - The narrative concludes with a strong call to action for investors to seize the opportunity presented by the AI and energy sectors, emphasizing the potential for significant returns within a short timeframe [15][19]

Group 1: Artisan Mid Cap Fund Performance - Artisan Mid Cap Fund's Investor Class fund ARTMX returned 8.80%, Advisor Class fund APDMX also posted a return of 8.80%, and Institutional Class fund APHMX returned 8.83% in Q3 2025, significantly outperforming the Russell Midcap Growth Index's return of 2.78% [1] - The strong performance was primarily driven by holdings in the health care sector [1] Group 2: DexCom, Inc. Overview - DexCom, Inc. (NASDAQ:DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems, with a market capitalization of $25.651 billion as of October 15, 2025 [2] - The stock experienced a one-month return of -13.68% and a 52-week decline of 5.95% [2] Group 3: Investment Decisions Regarding DexCom, Inc. - Artisan Mid Cap Fund ended its investment in DexCom, Inc. due to operational challenges and strong competition from Abbott's FreeStyle Libre platform, despite recognizing the significant opportunity in Type 2 diabetes [3] - The fund opted to exit its position in favor of companies with higher conviction profit cycles and more compelling valuations [3] Group 4: DexCom, Inc. Financial Performance - For Q2 2025, DexCom, Inc. reported global revenue of $1.16 billion, reflecting a 15% growth compared to $1 billion in Q2 2024 [4] - Despite the growth potential, the company is not among the 30 most popular stocks among hedge funds, with 60 hedge fund portfolios holding its stock at the end of Q2 2025, unchanged from the previous quarter [4]

Core Viewpoint - Investing in companies that have underperformed but show potential for long-term recovery can yield above-average market returns, exemplified by DexCom and Regeneron Pharmaceuticals, whose shares are down 17% and 21% this year respectively due to company-specific challenges [1]. DexCom - DexCom specializes in continuous glucose monitoring (CGM) systems for diabetes patients, facing challenges such as worse-than-expected financial results and a faster-than-anticipated rebate eligibility impacting revenue [3][4]. - In Q2, DexCom's revenue increased by 15% year-over-year to $1.2 billion, with non-GAAP net earnings per share at $0.48, reflecting an 11.6% increase compared to the previous year, indicating a rebound in financial performance [4]. - The CGM market presents significant growth opportunities, with over 4.5 million insulin patients in the U.S. eligible for coverage but not yet using CGM, and the launch of Stelo as an over-the-counter option for non-insulin patients further expands market potential [6][7]. - DexCom benefits from a network effect due to its large installed base and integration with third-party devices, which could help mitigate tariff threats through a multipronged strategy [7][8]. Regeneron Pharmaceuticals - Regeneron is working to overcome a recent patent cliff, indicating potential for future growth and recovery in its stock performance [8].

Core Insights - DexCom, Inc. is valued at a market cap of $25.5 billion and specializes in continuous glucose monitoring systems for diabetes management [1] - The company is expected to announce its fiscal Q3 earnings for 2025 on October 30, 2023 [1] Financial Performance - Analysts predict a profit of $0.57 per share for Q3 2025, representing a 26.7% increase from $0.45 per share in the same quarter last year [2] - For fiscal 2025, DexCom is expected to report a profit of $2.04 per share, up 24.4% from $1.64 per share in fiscal 2024, with further growth anticipated to $2.56 in fiscal 2026 [3] Stock Performance - DexCom shares have declined 4.7% over the past 52 weeks, underperforming the S&P 500 Index's 14.2% return, but have outperformed the Health Care Select Sector SPDR Fund's 7.5% decline [4] - Following better-than-expected Q2 results, DexCom's shares fell 9.3% in the subsequent trading session despite a 15.2% year-over-year revenue increase to $1.2 billion [5] Analyst Ratings - Wall Street analysts maintain a "Strong Buy" rating for DexCom, with 20 out of 27 analysts recommending "Strong Buy," one suggesting "Moderate Buy," and six indicating "Hold" [6] - The mean price target for DexCom is $100.24, suggesting a potential upside of 52.5% from current levels [6]

Core Viewpoint - DXCM is viewed as a defensive growth company that can maintain performance even if market conditions change [1] Group 1: Company Performance - The company is delivering relatively interesting figures, indicating strong operational performance [1] Group 2: Investment Strategy - The focus is on maintaining a delta neutral portfolio, allowing for long and short positions simultaneously to benefit from market volatility [1] - The investment strategy includes using options for entering and exiting trades, primarily targeting small to mid-sized companies [1]